EISAI CO LTD

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock



Company Profile

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial figures, Fiscal year: from 01.04. to 31.03.

	2024		2023		2022	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	722,237,000,000		621,847,000,000		640,260,000,000	
Common stock capital		44,986,000,000		44,986,000,000		44,986,000,000
Fixed assets	671,562,000,000		641,503,000,000		599,055,000,000	
Equity capital of a company		898,975,000,000		822,571,000,000		771,533,000,000
Cash and cash equivalents	304,678,000,000		267,350,000,000		309,633,000,000	
Accrued liabilities		1,413,000,000		1,299,000,000		1,473,000,000
Other assets	-		-		-	
Current liabilities		304,472,000,000		298,945,000,000		313,333,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		190,353,000,000		141,834,000,000		154,448,000,000
Different income		-		-		-
Other liabilities		15,730,000,000		19,096,000,000		19,407,000,000
Total assets	1,393,799,000,000	1,393,799,000,000	1,263,350,000,000	1,263,350,000,000	1,239,315,000,000	1,239,315,000,000

Balance notes

	2024	2023	2022
Accounting standard	IFRS	IFRS	IFRS
Employees	11,067	11,076	11,322
Equity ratio	66.17%	66.90%	64.09%
Debt-equity ratio	51.12%	49.48%	56.04%

Others

	2024	2023	2022
Tax Expense Rate	29.18%	-26.27%	16.05%

EISAI CO LTD

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock

Income statement			
	2024	2023	2022
Turnover	741,751,000,000	744,402,000,000	756,226,000,000
Net income	42,407,000,000	55,432,000,000	47,954,000,000
EBIT	335,004,600	264,461,000	337,695,400
Operating income before taxes	61,823,000,000	45,012,000,000	54,458,000,000
Cash Flow	55,993,000,000	-1,772,000,000	117,590,000,000
Net interest income	7,790,000,000	2,357,000,000	-9,000,000
Research and development expenses	153,092,000,000	156,691,000,000	158,030,000,000
Income taxes	18,040,000,000	-11,824,000,000	8,741,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	415,547	416,693	414,114

Board of Director	's
Clive Thornley	Member of Supervisory Board
Fumihiko Ike	Member of Supervisory Board
Hiroyuki Kato	Member of Supervisory Board
Kenta Takahashi	Member of Supervisory Board
Ryota Miura	Member of Supervisory Board
Takuji Kanai	Member of Supervisory Board
Toru Moriyama	Member of Supervisory Board
Yoshiteru Kato	Member of Supervisory Board
Yuko Yasuda	Member of Supervisory Board
Yumiko Miwa	Member of Supervisory Board

Members of Management Board			
Haruo Naito	Chairman of Managing Board		
Akiko Nakahama	Member of Executive Committee		
Gary Hendler	Member of Executive Committee		
Ivan Cheung	Member of Executive Committee		
Kazuhiko Tamura	Member of Executive Committee		
Keisuke Naito	Member of Executive Committee		
Kenta Takahashi	Member of Executive Committee		
Lynn Kramer	Member of Executive Committee		
Masatomi Akana	Member of Executive Committee		
Mitsuo Kosaka	Member of Executive Committee		
Mitsuru Shomon	Member of Executive Committee		
Sayoko Sasaki	Member of Executive Committee		
Shin Ujiie	Member of Executive Committee		
Shohei Kanazawa	Member of Executive Committee		
Takashi Owa	Member of Executive Committee		
Tatsuyuki Yasuno	Member of Executive Committee		
Terushige like	Member of Executive Committee		
Teruyuki Masaka	Member of Executive Committee		
Toshitaka Asano	Member of Executive Committee		
Yanhui Feng	Member of Executive Committee		
Yasushi Okada	Member of Executive Committee		